The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
The treatment is for patients with small cell lung cancer, which afflicts about 35,000 people in the U.S. a year. By Gina Kolata The Food and Drug Administration on Thursday approved an innovative ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen’s tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
The FDA has granted accelerated approval to IMDELLTRA™ for treating extensive-stage small cell lung cancer following platinum ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantel cell lymphoma. The agency has delay a decision on Dupixent in ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly ...